Mink Therapeutics Inc (INKT) - Total Liabilities
Based on the latest financial reports, Mink Therapeutics Inc (INKT) has total liabilities worth $23.64 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Mink Therapeutics Inc (INKT) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Mink Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Mink Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Mink Therapeutics Inc.
Mink Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Mink Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thinkific Labs Inc
TO:THNC
|
Canada | CA$19.80 Million |
|
EasyJet PLC
LSE:EZJ
|
UK | GBX9.08 Billion |
|
Bonus Biogroup
TA:BONS
|
Israel | ILA21.11 Million |
|
Sunsuria Bhd
KLSE:3743
|
Malaysia | RM1.27 Billion |
|
Talphera Inc.
NASDAQ:TLPH
|
USA | $12.40 Million |
|
Jade Gas Holdings Ltd
AU:JGH
|
Australia | AU$12.28 Million |
|
Isbir Sentetik Dokuma Sanayi AS
IS:ISSEN
|
Turkey | TL5.09 Billion |
|
HSS Engineers Bhd
KLSE:0185
|
Malaysia | RM178.00 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Mink Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Mink Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mink Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mink Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Mink Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $28.47 Million | +12.49% |
| 2024-12-31 | $25.31 Million | +11.94% |
| 2023-12-31 | $22.61 Million | +3.36% |
| 2022-12-31 | $21.87 Million | +32.84% |
| 2021-12-31 | $16.47 Million | -71.82% |
| 2020-12-31 | $58.43 Million | +55.22% |
| 2019-12-31 | $37.64 Million | -- |
About Mink Therapeutics Inc
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical tr… Read more